Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
CJC-1295 vs. Semaglutide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
CJC-1295 is distinguished by gHRH-receptor agonist family. The published human pharmacology appears to involve the long-acting DAC active moiety; non-DAC/Mod GRF forms are not interchangeable; Semaglutide is distinguished by single GLP-1 receptor agonist with multiple approved injection and tablet products and mature outcomes evidence.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
CJC-1295 is distinguished in the current record by gHRH-receptor agonist family. The published human pharmacology appears to involve the long-acting DAC active moiety; non-DAC/Mod GRF forms are not interchangeable. Semaglutide is distinguished by single GLP-1 receptor agonist with multiple approved injection and tablet products and mature outcomes evidence. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceSemaglutide
CJC-1295: Early human pharmacology. Semaglutide: Mature human evidence.
Regulatory historySemaglutide
CJC-1295: Not approved. Semaglutide: FDA approved for defined product-specific indications.
Mechanistic breadthComparable
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
CJC-1295
- Growth hormone and IGF-1 pharmacology
- Hormone pulsatility
- HIV-associated visceral obesity — terminated trial
Semaglutide
- Weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Chronic kidney disease
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
CJC-1295Not approved
Not FDA approved. FDA distinguishes five CJC-1295-related bulk substances across two active moieties; the 2024 PCAC voted against 503A Bulks List inclusion for the evaluated forms.
SemaglutideFDA-labeled indications
FDA approved in product-specific formulations for defined weight-management, type 2 diabetes, cardiovascular, kidney, and MASH indications.
Evidence depthEvidence, not a winner
CJC-1295Small PK/PD studies
Two small controlled human PK/PD studies, a small pulsatility analysis, and a terminated Phase 2 registration without posted results.
SemaglutideMature Phase 3 + outcomes
Multiple large Phase 3 programs and outcomes trials, including SELECT, FLOW, ESSENCE, STEP TEENS, and the higher-dose STEP UP program.
Weight outcomesEvidence, not a winner
CJC-1295No completed outcome trial
No completed controlled human weight- or body-composition outcome study was located. A visceral-obesity trial was terminated without posted results.
SemaglutidePeer-reviewed Phase 3
STEP 1 reported −14.9% mean change at 68 weeks with 2.4 mg versus −2.4% placebo. STEP UP later reported −18.7% with 7.2 mg, −15.6% with 2.4 mg, and −3.9% with placebo at 72 weeks.
Type 2 diabetesEvidence, not a winner
CJC-1295No dedicated evidence
No dedicated controlled human diabetes-outcome study was located.
SemaglutideApproved + extensive trials
Approved injection and oral products have extensive type 2 diabetes evidence. Product names, routes, strengths, and label instructions are not automatically interchangeable.
Obstructive sleep apnoeaEvidence, not a winner
CJC-1295No dedicated evidence
No dedicated controlled human obstructive-sleep-apnoea outcome study was located.
SemaglutideNo approved indication
No FDA-approved semaglutide indication for obstructive sleep apnoea was identified in the current U.S. labels.
Cardiovascular outcomesEvidence, not a winner
CJC-1295Long-term unknown
Long-term cardiovascular safety is unresolved. A Phase 2 participant died after myocardial infarction; the attending physician attributed the event to underlying coronary disease, and the trial published no results.
SemaglutideSELECT + labeled uses
SELECT demonstrated fewer major cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes. Other approved product labels cover defined diabetes populations.
Administration and handlingEvidence, not a winner
CJC-1295DAC research arms only
Human pharmacology used protocol-defined subcutaneous CJC-1295 DAC. This does not establish an approved dose, route, schedule, or handling process for DAC, non-DAC, or named salt products.
SemaglutideMultiple product-specific labels
Current FDA labels include weekly subcutaneous injections and daily oral tablets with product-specific administration, switching, and storage instructions. Approved products require no reconstitution.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Clinical outcomes, long-term safety, product identity, and whether any findings apply to non-DAC/Mod GRF(1-29).
- Long-term comparative outcomes across newer products and doses, rare events at population scale, and evidence outside studied populations or approved products.
Community Intelligence
Emerging patterns, clearly separated from evidence
CJC-1295
No community experiences yetBe the first account holder to contribute.
Semaglutide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.